Postoperative radiotherapy after radical prostatectomy significantly improves biochemical progression-free survival and local control
A clinical trial conducted by the EORTC Radiation Oncology and Genito-Urinary Groups and reported in The Lancet suggests that postoperative radiotherapy (P-RT) following radical prostatectomy (RP) significantly improves biochemical progression-free survival (BPFS) and local control. Exploratory analyses also suggest that P-RT might improve clinical progression-free survival (PFS) in patients younger than 70 years of age and in patients with positive surgical margin.
In an article appearing in the European Journal of Cancer, the EORTC’s Denis Lacombe, Susen Burock, and Françoise Meunier discuss the urgent need to develop new models of partnership between academia and industry for early-stage cancer clinical research. Much progress has been made in unraveling the molecular mechanisms and pathways of cancer, and this has inevitably led to the incorporation of translational medicine into the design of clinical trials.
